Home
ACE Reports
All Specialties All Specialties All Specialties Arthroplasty Arthroplasty Arthroplasty Evidence Based Medicine Evidence Based Medicine Evidence Based Medicine Foot & Ankle Foot & Ankle Foot & Ankle General Orthopaedics General Orthopaedics General Orthopaedics Hand & Wrist Hand & Wrist Hand & Wrist Metabolic Disorders Metabolic Disorders Metabolic Disorders Osteoarthritis Osteoarthritis Osteoarthritis Pediatric Orthopaedics Pediatric Orthopaedics Pediatric Orthopaedics Peri-Operative Peri-Operative Peri-Operative Physical Therapy & Rehab Physical Therapy & Rehab Physio & Rehab Shoulder & Elbow Shoulder & Elbow Shoulder & Elbow Spine Spine Spine Sports Medicine Sports Medicine Sports Medicine Trauma Trauma Trauma Tumour Tumour Tumour Author Interviews Author Interviews Author Interview Conference Report Conference Report Conference Reports
Original Content
News
Multimedia
About
Search
Home
ACE Reports
Arthroplasty Evidence Based Medicine Foot & Ankle General Orthopaedics Hand & Wrist Metabolic Disorders Osteoarthritis Pediatric Orthopaedics Peri-Operative Physical Therapy & Rehab Shoulder & Elbow Spine Sports Medicine Trauma Tumour Author Interviews Conference Report
Original Content
News
Multimedia
About
Search
Previous Ace Report No difference in clinical outcomes between operative and non-operative treatment for 2-part PHF Next Ace Report Buddy taping displays similar re-displacement rate, more comfort, vs splint for pediatric finger Frx
Ace Report Cover
Sports Medicine
Benefit of BM-MSC addition in core decompression in treatment of osteonecrosis of the femoral head
Reprints
Cite This
Reprints
Cite This
AceReport Image
Sports Medicine
Benefit of BM-MSC addition in core decompression in treatment of osteonecrosis of the femoral head
Int J Surg. 2019 Jul 10;69:23-31
Contributing Authors

Z Wang QM Sun FQ Zhang QL Zhang LG Wang WJ Wang

14 randomized controlled trials were included in this meta-analysis which sought to investigate the impact of autologous bone marrow-derived mesenchymal stem cell (MSC) administration alongside core decompression on outcomes in treatment of patients with osteonecrosis of the femoral head. Pooled analyses of pain scores from 6 months to 2 years, function from 1 to 2 years, and incidence of eventual total hip arthroplasty, ranging from 1 to 5 years in the same analysis, all significantly favoured MSC groups compared to control groups.

Unlock the full article

Get unlimited access to OrthoEvidence with a free trial
Start Trial

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or continue reading this full article
Register Now
AskOE
Search
Close Search Window
Welcome Back!
Forgot Password?
Create an Account

Account will be affiliated with

OR
Forgot Password?
OR
Check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see the email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. Benefit of BM-MSC addition in core decompression in treatment of osteonecrosis of the femoral head. ACE Report. 2019;9(8):9. Available from: https://myorthoevidence.com/AceReport/Report/benefit-of-bm-msc-addition-in-core-decompression-in-treatment-of-osteonecrosis-of-the-femoral-head

Copy Citation
Share this Ace Report